JUPITER BIOSCIENCE LIMITED
ANNUAL REPORT 2010-2011
The past financial year was an exceptional year considering the industry
scenario and uncertain global economy. During the past year, your company
continued its growth path by launching Generic Peptide APIs, APIs based on
organic chemistry and Chiral Intermediates which strengthened its product
pipeline. Your company's progress and achievement during the year indicated
the progress and fulfillment of goals and objectives.
During the financial year, the company fortified its presence in the
regulatory markets through its subsidiaries located in Switzerland and USA.
The sales for the year was Rs. 253.10 Crores which was 37.60% increase over
the previous year. The Profit after tax for the year was Rs. 37.59 Crores
which was 13.44% increase over the previous year. Hence your company is on
the growth path.
Your company is well-equipped for the slow but positive development in our
markets with a diverse product portfolio of more than 400products which
includes Peptide Building Blocks and APIs, High end Intermediates and APIs
based on Organic Chemistry which was further expanded in the year under
Your company remains fully committed to its vision and long-term strategy.
We continue to invest significantly in Research and Development to
strengthen our position in Peptides and Generic products and create new
Venkat R. Kalavakolanu
Chairman & Managing Director